Catalyst Pharmaceuticals Inc (NASDAQ:CPRX)’s share price traded down 5.5% during mid-day trading on Tuesday . The company traded as low as $3.24 and last traded at $3.24. 614,802 shares changed hands during trading, an increase of 19% from the average session volume of 515,250 shares. The stock had previously closed at $3.43.
A number of equities analysts have recently issued reports on the company. BidaskClub downgraded Catalyst Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Saturday, January 6th. Zacks Investment Research raised Catalyst Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Tuesday, October 31st. HC Wainwright reaffirmed a “buy” rating and set a $6.00 price target on shares of Catalyst Pharmaceuticals in a research report on Thursday, December 21st. SunTrust Banks reaffirmed a “buy” rating and set a $6.00 price target on shares of Catalyst Pharmaceuticals in a research report on Wednesday, November 29th. Finally, Piper Jaffray Companies set a $8.00 price target on Catalyst Pharmaceuticals and gave the stock a “buy” rating in a research report on Friday, December 1st. Two equities research analysts have rated the stock with a sell rating and four have given a buy rating to the stock. Catalyst Pharmaceuticals presently has a consensus rating of “Hold” and an average price target of $6.25.
The stock has a market capitalization of $278.79, a PE ratio of -15.43 and a beta of 1.35.
Several hedge funds have recently modified their holdings of CPRX. Two Sigma Securities LLC grew its holdings in shares of Catalyst Pharmaceuticals by 132.2% during the fourth quarter. Two Sigma Securities LLC now owns 26,658 shares of the biopharmaceutical company’s stock valued at $104,000 after buying an additional 15,178 shares during the last quarter. Caxton Corp purchased a new stake in shares of Catalyst Pharmaceuticals during the fourth quarter valued at $129,000. MetLife Investment Advisors LLC purchased a new stake in shares of Catalyst Pharmaceuticals during the fourth quarter valued at $144,000. Nationwide Fund Advisors purchased a new stake in shares of Catalyst Pharmaceuticals during the second quarter valued at $111,000. Finally, New York State Common Retirement Fund purchased a new stake in shares of Catalyst Pharmaceuticals during the second quarter valued at $114,000. 39.98% of the stock is currently owned by institutional investors and hedge funds.
ILLEGAL ACTIVITY NOTICE: “Catalyst Pharmaceuticals (CPRX) Stock Price Down 5.5%” was originally published by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are viewing this piece on another publication, it was copied illegally and republished in violation of US and international trademark & copyright legislation. The original version of this piece can be read at https://www.dispatchtribunal.com/2018/02/20/catalyst-pharmaceuticals-cprx-stock-price-down-5-5.html.
Catalyst Pharmaceuticals Company Profile
Catalyst Pharmaceuticals, Inc, formerly Catalyst Pharmaceutical Partners, Inc, is a development-stage biopharmaceutical company. The Company is focused on developing and commercializing therapies for people with rare debilitating diseases. The Company has three drugs in development: Firdapse, CPP-109 and CPP-115.
Receive News & Ratings for Catalyst Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalyst Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.